Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma

1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have a median progression-free survival and overall survival of 22.5 months. Evidence Rating Level: 2 (Good) Study Rundown: Solid organ transplant recipients receiving chronic immunosuppression have an increased risk of cutaneous squamous cell carcinoma (CSCC). Cemiplimab, […]

The post Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma first appeared on 2 Minute Medicine.